Insulin Ryzodeg for type 2 diabetes launched
Novo Nordisk, a global leader in diabetes care, launched Ryzodeg -- insulin for type 2 diabetes -- in Bangladesh yesterday.
Bangladesh is the third country after Mexico and India to launch such a type of insulin, said Maziar Mike Doustdar, senior vice president for international operation of Novo Nordisk, at a press conference at The Daily Star Centre in the capital.
Currently, the country has close to 5.9 million people with diabetes. The figure is expected to double by 2030, he added.
Diabetics who use basal-bolus regimens may need to take up to four injections daily, but with Ryzodeg they only need to take two injections, said Doustdar.
The modern insulin will play a significant role in fighting diabetes in Bangladesh, said Camilla Sylvest, corporate vice president of Novo Nordisk, Oceania and South East Asia region.
Ryzodeg is expected to help people with diabetes who were dependent on separate basal and bolus injections in improving their quality of life, said Mohammad Saiful, head of marketing of Novo Nordisk Pharma in Bangladesh.
Novo Nordisk has been a partner of Transcom Distribution Company since 2006. It is the importer and distributor of Novo Nordisk insulin Bangladesh. Novo Nordisk also produces human insulin vial at high-tech manufacturing plant at Eskayef Bangladesh, a pharmaceutical company.
Comments